amivantamab
janssen,genmab
['9008']
 abstract 9008. amivantamab for metex14 with orr 50% in tx-naive group and 17% in pre-treated group. probably not good option post met tkis. what is cns activity in this group? and do aes (risk of infusion reaction) of ami outweigh benefit of met tki? #asco22 
Thoracic oncologist @ CU | Interested in targeted therapies and novel biomarkers | Dabble with piano, film, and skiing on the side | Alum @Penn & @KeckMedUSC